New pill takes on Hard-to-Treat cancers in first human trial

NCT ID NCT05159700

Ongoing Disease control Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRJ1-3024 (oral capsule)
What this could lead to: If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 39 participants. The main goal is safety, not effectiveness. Many drugs fail at this stage, and side effects may be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hereditary sensory and autonomic neuropathy neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCIES ADVANCED SOLID TUMOR

Contacts and locations

Locations

Christ Hospital

Cincinnati, Ohio, 21073, United States
Mays Cancer Center

San Antonio, Texas, 78229, United States
NEXT Oncology

Austin, Texas, 73301, United States
NEXT Oncology

Fairfax, Virginia, 22031, United States
Sarah Cannon Research Institute at Florida Cancer Specialists

Orlando, Florida, 32827, United States
Sarah Cannon Research Institute at HealthONE

Denver, Colorado, 80218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.